BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.2.1//EN TZID:Asia/Jerusalem X-WR-TIMEZONE:Asia/Jerusalem BEGIN:VEVENT UID:1040@biology.technion.ac.il DTSTART;TZID=Asia/Jerusalem:20220126T130000 DTEND;TZID=Asia/Jerusalem:20220126T140000 DTSTAMP:20220117T111224Z URL:https://biology.technion.ac.il/en/seminars/phd-graduate-seminar-abraha m-rutenberg/ SUMMARY:PhD. Graduate Seminar- Abraham Rutenberg [No Categories] DESCRIPTION:Location: Faculty of Bilogy Auditorium \n Affiliation: \n Host :\n Tcell starvation and nutrient competition at the tumor micro environme nt is considered a major limiting factor in cancer immunotherapy. Metaboli c suppression hampers T cell activation\, differentiation\, and effector f unctions\, leading to T cell anergy and apoptosis\, resulting in tumor esc ape and immunotherapy failure. We propose a novel nanotechnology-based app roach to overcome metabolic T cell suppression: specific feeding of T cell s with nanoparticles encapsulating essential metabolites during the ex-viv o phase of adoptive CAR Tor TIL therapy. This creates an internal cellular reservoir of controlled release nutrients that will support T cell metabo lic requirements upon reaching the nutrient-depleted tumor microenvironmen t. In order to achieve high metabolite loading\, we use a core-shell archi tecture in which we polymerize a nano-meter silica shell on a nano-sized c ore of the desired metabolite obtained by grinding. By controlling the sol -gel synthesis parameters we can tailor shell thickness and porosity and d etermine metabolite release rate and encapsulation efficiency. Our prelimi nary work focuses on L-arginine as a model system – one of the keys most important amino acids for T cell activation depleted at the tumor microen vironment of many cancers. We generate arginine-loaded nanoparticles and d emonstrated arginine-controlled release kinetics. In order to enable T cel l uptake\, we conjugate anti-CD3 antibodies to the nanoparticle surface. F inally\, we demonstrate that arginine starvation leads to inhibition of T cell proliferation\, reduced activation markers expression\, and impaired survival\; while prior feeding of the T cells with arginine-encapsulating nanoparticles partially rescues the activation phenotype. Based on these p reliminary results we propose that feeding T cells with metabolite encapsu lating nanoparticles may potentially relieve metabolic immune suppression in adoptive cell therapies and result in superior CAR T andTIL cancer immu notherapies. LOCATION:Faculty of Bilogy Auditorium END:VEVENT BEGIN:VTIMEZONE TZID:Asia/Jerusalem X-LIC-LOCATION:Asia/Jerusalem BEGIN:STANDARD DTSTART:20211031T010000 TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:IST END:STANDARD END:VTIMEZONE END:VCALENDAR